| 
        
          |  |  Having spent most of my life in logistics, 
        when we started talking about COVID-19 vaccines in the springtime last 
        year, I was anticipating the greatest logistics challenge of our times: 
        delivering COVID19 vaccines as soon as available to thousands if not millions 
        of Point of use (POU’s) [see below] all over the world. Famously 
        we recall challenges such as the Berlin airlift which kept west Berlin 
        alive in times of cold war, perhaps less famously but even more challenging 
        we record the yearly feat of delivering the Beaujolais Nouveau wine to 
        the five continents, ready for its grand opening every autumn. 2020, a 
        year loathed by most, nonetheless witnessed the kick-start of the largest 
        logistics operation of all times. We have had ways of understanding that 
        2020 is one of a kind. This is especially true in logistics, and will 
        be on our records for many years to come.
 We have all become familiar with the logo 
        of the John Hopkins University in these long pandemic months; sometimes 
        we use their precious resources superficially, looking at their figures 
        with insufficient knowledge on our side, but JHU.edu is also a resource 
        allowing for more elaborate consideration, for example they have amply 
        discussed the efficient and equitable logistics of vaccine distribution 
        in this article, 
        in so doing, they are echoing other concerns voiced inter alia by the 
        WHO or UNICEF.
 The Shot in the Arm for Countless Billions
 
 Just to give you an idea of the magnitude 
        of the challenge, I am resorting to figures published by Nature on Nov 
        30th: “the makers of the three vaccines that seem closest to widespread 
        distribution — AstraZeneca, Pfizer and Moderna — estimate 
        a total production capacity of 5.3 billion doses for 2021, which could 
        cover between 2.6 billion and 3.1 billion people, depending on whether 
        AstraZeneca’s vaccine is administered in two doses or one and a 
        half. And a vaccine created at the Gamaleya National Center of Epidemiology 
        and Microbiology in Moscow could cover another 500 million people per 
        year outside Russia from 2021, says the Moscow-based Russia Direct Investment 
        Fund.
 A Glimpse of a Logistics Challenge 
        for all Time
 
 Anyone dealing with logistics quickly understands 
        that delivering anything as big as 5 billion doses worldwide in a year, 
        on top of whatever else moves already on planes, ships, trucks and trains, 
        doest not happen by magic, but will require an exceptional deployment 
        of resources and expertise.
 Tapping on the information provided by Deutsche 
        Post DHL, the infographics published on line by the multinational show 
        us the dimensions of the challenge: if you combine the item movements 
        shown below with the number of vaccine doses that need to be delivered 
        the result is mind-boggling.
 
        
          |  |   But the challenges do not come from numbers alone. 
        This is what Pfizer announced [abridged PR] on Nov 20th about the behemoth 
        operation on its way:
 •  
        During the initial stage, our contracts are with governments, 
        and we will be providing doses according to their preferred channel and 
        designated vaccination locations, subject to regulatory authorization 
        or approval.
 •  
        We have developed detailed logistical plans and tools 
        to support effective vaccine transport, storage and continuous temperature 
        monitoring. Our distribution is built on a flexible, just-in-time system, 
        which will ship the frozen vials direct to the point of vaccination.
 •  
        In the U.S., our distribution approach will be to largely 
        ship from our Kalamazoo, Michigan, site direct to the point of use (POU). 
        We also will use our existing distribution center in Pleasant Prairie, 
        Wisconsin.
 •  
        We will be utilizing road and air modes of transportation 
        in the United States, where we expect to be able to get product to any 
        POU within a day or two.
 •  
        We also have developed packaging and storage innovations 
        to be fit for purpose for the range of locations where we believe vaccinations 
        will take place. We have specially designed, temperature-controlled thermal 
        shippers utilizing dry ice to maintain recommended storage temperature 
        conditions of -70°C±10°C for up to 10 days unopened. The 
        intent is to utilize Pfizer-strategic transportation partners to ship 
        by air to major hubs within a country/region and by ground transport to 
        dosing locations.
 •  
        We will utilize GPS-enabled thermal sensors with a control 
        tower that will track the location and temperature of each vaccine shipment 
        across their pre-set routes, 24 hours a day, seven days a week. These 
        GPS-enabled devices will allow Pfizer to proactively prevent unwanted 
        deviations and act before they happen.
 •  
        Once a POU receives a thermal shipper with our vaccine, 
        they have three options for storage:
 * 
        - Ultra-low-temperature freezers, which are commercially available 
        and can extend shelf life for up to six months.
 * 
        -The Pfizer thermal shippers, in which doses will arrive, that 
        can be used as temporary storage units by refilling with dry ice every 
        five days for up to 30 days of storage.
 * 
        -Refrigeration units that are commonly available in hospitals. 
        The vaccine can be stored for five days at refrigerated 2-8°C conditions.
 •  
        After storage for up to 30 days in the Pfizer thermal 
        shipper, vaccination centers can transfer the vials to 2-8°C storage 
        conditions for an additional five days, for a total of up to 35 days. 
        Once thawed and stored under 2-8°C conditions, the vials cannot be 
        re-frozen or stored under frozen conditions.
 Pfizer Speaks and Brussels Sprouts
 
 The news came at 11.30 EST on Dec 13th 2020 
        that Pfizer had started shipping vaccine doses from Michigan. This is 
        public knowledge now as is, albeit less widely advertised, that the European 
        Pfizer vaccine will come from a village between Brussels and Antwerp, 
        Puur.
 
  Jean 
        Claude Served DHL In Brussels 
 After reading Pfizer’s challenging 
        conditions, I thought I would resort to the knowledge and experience of 
        my old friend Jean-Claude Delen, who served as director in DHL in Brussels, 
        as well as being President of CLECAT between 2005 and 2009 and subsequently 
        of FIATA, more or less at the time when I worked as DG in both associations 
        successively.
 Jean-Claude is the rare pearl that both 
        federations have tried to keep at their helm as long as allowed by their 
        individual statutes.
 He is currently presiding the FIATA Foundation, 
        after serving also as Treasurer of FIATA for a number of years. In his 
        various institutional positions in Brussels Jean-Claude strongly contributed 
        to the development of a state of the art facility at Brussels Airport, 
        which boosts a cool storage capacity second to none. Similar arrangements 
        were made in Liege, albeit at a smaller echelon. Having made such wise 
        investments in the past proves to be crucial today and explains why Belgium 
        is often chosen as the production and distribution centre for the whole 
        of Europe by many pharmaceutical enterprises.
 United Leads The Way 
 On Nov 27th United Airlines announced the 
        first “mass shipment” of Pfizer’s vaccines from Brussels 
        to O’Hare in Chicago.
 So hats off to Jean-Claude who was able 
        to don the cloak of the master of the understatement, when he said “I 
        am aware that we have the infrastructure in place to work on the vaccine 
        delivery programme, at least for the part that is produced in Belgium.”
 Jean-Claude also caught a flying ember today, 
        when he pointed to out to me that “GSK have vouched millions in 
        investments in Belgium, which appears to be a U-turn from their February 
        2020 statement announcing nearly 1,000 job cuts.”
 
         
          |  |  How Vaccine Delivers In Europe
 
 It is understandable that the proximity 
        between the logistics infrastructure and the production sites has already 
        allowed Pfizer to start delivering its vaccine within Europe, but we should 
        not forget that the efficient delivery of so many consignments of vaccine 
        requires resources and these need to be trained. I heard from some of 
        my acquaintances in Brussels that training has been on the tables for 
        quite some time now.
 There is anyway considerable confidentiality 
        regarding the arrangements surrounding the vaccination programme in many 
        countries, including mine.
 La Dolce Vita
 
 In Italy the special Commissioner Arcuri appears 
        to have decided that vaccine doses will be delivered by the Italian Army 
        for the time being. Fedespedi and ANAMA, whose members had been bracing 
        for the possible extra load coming from the vaccine distribution have 
        been informed that, at least in the beginning, the doses will be handled 
        by the military and will be stored in secured areas.
 Understandably there is concern about the complexity 
        of the logistic chain and the safety and security of the vaccine. As Pfizer 
        stated, this is governments’ affair and there is no private handling 
        of vaccines, at least for the time being since no parallel market exists. 
        Nobody wishes to talk openly about the issue, but it is clear that ministers 
        are concerned that vaccines could get into the wrong hands, although the 
        stringent requirements for safely handling the vaccine are a form of insurance 
        in itself.      This is not something you can 
        place at the back of your car, it requires a sophisticated delivery system. 
        Needless to say the freight logistics community in Italy will respond 
        if they are called to assist in the operations, as it will most likely 
        happen as this year moves along.
 Focus Germany
 
 If we remain in Europe it is nearly impossible 
        to avoid looking at what happens in Germany, the largest country in the 
        EU, which is in the middle of a second wave of infections right now. The 
        following information comes from a well-informed online source:
 The transport, storage and distribution 
        of the highly temperature-sensitive vaccines (-70°C) pose an enormous 
        challenge. The company VA-Q-Tec in Würzburg, a specialist in cool 
        boxes, has already received an order worth millions: "transport will 
        take place in our containers and boxes," says CEO Joachim Kuhn. Ultra-low 
        freezers are also required for storage. They come from the Swabian company 
        Binder, each unit comes at around €20,000 euros. Frankfurt Airport, 
        a proven transhipment point for cool-chain pharmaceuticals, is warming 
        up. "We are preparing for both import and export," says Fraport 
        manager Max Philipp Conrady. “We don't yet know what's coming and 
        what will be produced where.” In terms of quantities, however, the 
        corona vaccine is not an “overwhelming challenge” [for Fraport], 
        as 13,500 square meters of temperature-controlled storage are available.
 Deutsche Post DHL, based in Bonn, 
        with more than 180 locations around the world tailored to the needs of 
        the pharmaceutical industry, is confident to store and transport medicines 
        for up to three days at a constant low temperature, which can reach -80°C). 
        The logistics group Kuehne + Nagel, headquartered in Bremen, is also involved 
        in the distribution: "It will be a challenge, but nothing where we 
        say: that’s impossible", said CEO Detlef Trefzger.
 In conclusion we can perhaps look 
        at this epochal challenge with reasonable confidence. Our companies are 
        responsive and are gearing up to the dimensions that will be required 
        by the challenge. At this point the only risk is overconfidence, which 
        is the perfect recipe to sleepwalk into a disaster. All hands on deck 
        and eyes wide open we can make it, but we must remain alert and focussed.
 Stay safe all of you there, with 
        my best wishes for the year ahead.
 Marco L. Sorgetti
 Turin
 |